Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
29 hedge funds and large institutions have $2.99M invested in Vyant Bio, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
3% less funds holding
Funds holding: 30 → 29 (-1)
26% less capital invested
Capital invested by funds: $4.04M → $2.99M (-$1.05M)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$203K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$176K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$137K |
| 4 |
Squarepoint
New York
|
+$46.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$27.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$476K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$130K |
| 3 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$63K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$56.2K |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$28K |
VYNT Hedge Fund Activity: Q4 2016 in Review
29 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2016, worth a combined $2.99M — down 26% from $4.04M a quarter earlier.
Fund positioning in VYNT was balanced in Q4 2016: 6 funds opened new positions, 6 closed out, 4 added to existing stakes and 9 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $203K. The largest seller was Anson Funds Management, exiting entirely with an estimated $476K sold.
- 29 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2016, down from 30 in Q3 2016.
- Funds reported $2.99M of Vyant Bio, Inc. Common Stock stock for Q4 2016, down 26% quarter-over-quarter.
- 6 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2016 and 6 closed out, a net change of 0 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2016 was Renaissance Technologies, an estimated $203K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2016 was Anson Funds Management, an estimated $476K sold.
Based on aggregated 13F filings for Q4 2016.